TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: PNRCH    
Drug Immunoassay Panel, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting drug use involving barbiturates, cocaine, and tetrahydrocannabinol

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol. Positives are confirmed and quantitated by definitive methods (gas chromatography-mass spectrometry for barbiturates, cocaine and metabolites, and tetrahydrocannabinol metabolite) at an additional charge.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This test uses the simple screening technique that involves immunologic testing for drugs by class. All positive immunoassay screening results are confirmed by gas chromatography-mass spectrometry (GC-MS) and quantitated before a positive result is reported.

 

This assay was designed to test for and confirm by GC-MS the following:

-Barbiturates

-Cocaine

-Tetrahydrocannabinol

 

This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Only orderable as part of profile. For more information see CSMPU / Controlled Substance Monitoring Panel, Random, Urine.

 

Negative

Screening cutoff concentrations:

Barbiturates: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

 

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Interpretation Provides information to assist in interpretation of the test results

A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past. See individual tests (eg, COKEU / Cocaine and Metabolite Confirmation, Random, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not intended for use in employment-related testing.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Physicians' Desk Reference: 60th ed. Medical Economics Company; 2006

2. Bruntman LL ed. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Book Company; 2006

3. Langman LJ, Bechtel L, Meier BM, Holstege CP: Clinical toxicology In: Rifai N, Horwath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed.  Elsevier; 2018:832-887

4. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526